Literature DB >> 12628454

The expression and biological role of the non-neuronal cholinergic system in the ovary.

Artur Mayerhofer1, Nicola Dimitrijevic, Lars Kunz.   

Abstract

Functioning of the ovary depends on an interplay between hormones, locally produced growth factors and neurotransmitters. Neurotransmitters are delivered to the ovary via its sympathetic innervation and originate from intrinsic nerve cells expressing catecholaminergic and peptidergic traits. We found that the nerve fibers and nerve cells of the ovary were however not immunoreactive for the ACh-synthesizing enzyme, choline-acetyl transferase (ChAT). Immunoreactivity was instead detected in ovarian endocrine cells, namely granulosa cells (GCs), of rodents and primates. Importantly, isolated GCs produce ACh. Thus, endocrine cells are an unexpected non-neuronal source of ACh in the ovary. GCs in vivo and in vitro also contain ACh-receptors of the muscarinic subtype (MR), namely M1 and M5. MR of human GCs are functional and linked to rapid increases in intracellular calcium levels. A role of ovarian ACh/MR in the crucial process of cell proliferation is suggested by the observation that in growing follicles, ChAT-immunoreactive GCs co-express "proliferating cell nuclear antigen" (PCNA) and that cholinergic agents stimulate cell proliferation of human GCs in vitro. This proliferative effect is associated with rapid disruption of gap junction communication and phosphorylation of connexin 43. In addition, calcium-dependent channels are activated. Ongoing studies have begun to identify down-stream effects of M1/5 activation in GCs, which include, for example, expression of a transcription factor (egr-1). In summary, ovarian endocrine cells are sources and targets of ACh. We propose that an as yet unexplored intraovarian cholinergic system exists, which contributes to physiological ovarian tissue remodeling by stimulation of cell proliferation. Copyright 2003 Published by Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628454     DOI: 10.1016/s0024-3205(03)00081-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Ovulation requires the activation on proestrus of M₁ muscarinic receptors in the left ovary.

Authors:  M E Cruz; A Flores; B E Alvarado; C G Hernández; A Zárate; R Chavira; M Cárdenas; I Arrieta-Cruz; R Gutiérrez-Juárez
Journal:  Endocrine       Date:  2015-01-14       Impact factor: 3.633

2.  Identification of cholinergic cells with chemosensory traits in the porcine uterus.

Authors:  Mariana Sponchiado; Yan-Shin Liao; Leah R Reznikov
Journal:  Cell Tissue Res       Date:  2022-01-27       Impact factor: 5.249

3.  Functional promoter polymorphisms govern differential expression of HMG-CoA reductase gene in mouse models of essential hypertension.

Authors:  Parshuram J Sonawane; Bhavani S Sahu; Binu K Sasi; Parimala Geedi; Govinda Lenka; Nitish R Mahapatra
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

4.  The acute asymmetric effects of hemiovariectomy on testosterone secretion vary along the estrous cycle. The participation of the cholinergic system.

Authors:  Angélica Flores; Jorge O Rodríguez; María T Palafox; Griselda Meléndez; Ana I Barco; Roberto Chavira; M Esther Cruz; Roberto Domínguez
Journal:  Reprod Biol Endocrinol       Date:  2006-03-01       Impact factor: 5.211

5.  The role of the muscarinic system in regulating estradiol secretion varies during the estrous cycle: the hemiovariectomized rat model.

Authors:  María E Cruz; Angélica Flores; María T Palafox; Griselda Meléndez; Jorge O Rodríguez; Roberto Chavira; Roberto Domínguez
Journal:  Reprod Biol Endocrinol       Date:  2006-08-21       Impact factor: 5.211

6.  FSH regulates acetycholine production by ovarian granulosa cells.

Authors:  Artur Mayerhofer; Lars Kunz; Annette Krieger; Becky Proskocil; Eliot Spindel; Abraham Amsterdam; Gregory A Dissen; Sergio R Ojeda; Ignaz Wessler
Journal:  Reprod Biol Endocrinol       Date:  2006-07-17       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.